Metraipolis › archive › dc_862a8291ca23

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma — Europe PMC PMID:42115674

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42115674
DOI
10.1038/s41409-[numero omesso]-w
License (as archived)
solo-consultazione
Archived
2026-10-15T17:19:08.432Z
SHA-256 of the archived text
4d0d086659e815e559240f2d97d2ebd6288a24abb6911c1cf7830d7b757fa1bf
Stable URL of this page
https://metraipolis.com/documento/dc_862a8291ca23

How to cite

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma — Europe PMC PMID:42115674 — Europe PMC (en), https://europepmc.org/article/MED/42115674 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_862a8291ca23 (Metraipolis archive dc_862a8291ca23, sha256 4d0d086659e815e559240f2d97d2ebd6288a24abb6911c1cf7830d7b757fa1bf)
BibTeX
@misc{dc862a8291ca23,
  title = {Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma — Europe PMC PMID:42115674},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42115674},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_862a8291ca23; sha256 4d0d086659e815e559240f2d97d2ebd6288a24abb6911c1cf7830d7b757fa1bf},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42115674. Agents can read the archived copy with the MCP tool read_document.